Cagrilintide monotherapy for treatment of obesity In a 26-week phase 2 trial (n=706, 62 Percentage women, mean age 52 years), cagrilintide was evaluated in 5 groups of subjects receiving 0.3, 0.6, 1.2, 2.4, and 4.5 mg/week as treatment for obesity in comparison with liraglutide 3.0 mg/day, and placebo (table 1) [9]
This substrate site-targeting mechanism provides selectivity over related methyltransferases and other NAD salvage pathway enzymes in laboratory assay systems
KPV (10mg) is a tripeptide composed of lysine, proline, and valine, derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH)
Here's What's Actually Happening 2025-07-18 Alcohol and Mounjaro: Why Drinking Makes You Feel Sick, and What to Do About It 2025-07-25 Weight Loss Drug Mounjaro May Slow Breast Cancer Growth in Mice, Early Study Finds 2025-08-21 Wegovy and the STEP UP Trial Results: What You Need to Know 2026-07-12 Is Porridge Good for Weight Loss
